CN102430095A - Medicine for treating lung cancer - Google Patents
Medicine for treating lung cancer Download PDFInfo
- Publication number
- CN102430095A CN102430095A CN2011103852955A CN201110385295A CN102430095A CN 102430095 A CN102430095 A CN 102430095A CN 2011103852955 A CN2011103852955 A CN 2011103852955A CN 201110385295 A CN201110385295 A CN 201110385295A CN 102430095 A CN102430095 A CN 102430095A
- Authority
- CN
- China
- Prior art keywords
- gram
- medicine
- lung cancer
- powder
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating lung cancer, and aims to screen natural Chinese herbal medicines with the effects of tonifying qi and eliminating pathogens, removing stasis and clearing phlegm, and dissipating hardness and stagnation according to the cognition of motherland medicine and traditional medicine to a pathogenic mechanism of lung cancer and a treatment principle of lung cancer by consulting the modern pharmacological research. The medicine is prepared from the following components by weight: 12g of ginseng, 16g of astragalus, 12g of safflower, 18g of turmeric root-tuber, 15g of tangerine peel, 10g of costustoot, 15g of blackberrykiky rhizome, 15g of cattail pollen, 18g of spreading hedyotis herb, 20g of chicken's gizzard-membrane and 20g of Chinese sage herb. The components are uniformly mixed and ground into fine powder of 150 meshes, the fine powder is packed into bags, and each bag contains 8g of medicine powder.
Description
Technical field the invention belongs to technical field of Chinese medicines, relates to a kind of treatment lung cancer drugs, is the Chinese patent medicine of feedstock production specifically with the Chinese herbal medicine.
The tumor cell of background technology pulmonary carcinoma comes from bronchial mucosa or body of gland; Regional lymph node and hematogenous spread are often arranged; So even patient's postoperative still has the probability of cancer return; Pulmonary carcinoma postoperative chemotherapeutics commonly used carries out chemotherapy or radiotherapy at present, but the side effect of chemotherapeutics is huge, can bring other severe complications to human body.Having many patients to make a definite diagnosis now is refusal operation after the pulmonary carcinoma, and this makes troubles for the clinical position person.Motherland's medical science thinks that pulmonary carcinoma belongs to " lump in the right hypochondrium " category of Chinese medicine, and the origin cause of formation of primary disease, Chinese medicine think that positive QI-insufficiency, evil poison invade lung and cause the respectful mistake department of falling of lung qi, and lung qi stasis is not declared, and then blood stasis expectorant coagulates, and then forms lump for a long time.Chinese medicine is eliminating evil in QI invigorating, tool is with huge advantage aspect the blood stasis dispelling clearing away phlegm, the hard eliminating stagnation that disappears, and inventing therefore that a kind of treatment lung cancer drugs treats should disease.
Summary of the invention the purpose of this invention is to provide a kind of, blood stasis dispelling clearing away phlegm eliminating evil with QI invigorating, the hard eliminating stagnation that disappears is the treatment lung cancer drugs of the rule of treatment, to overcome the deficiency of prior art.
The objective of the invention is according to pathogenetic understanding and the Therapeutic Principle thereof of motherland's medical tradition medical science pulmonary carcinoma; With reference to modern pharmacological research; Filter out therefrom that QI invigorating is eliminating evil, the natural Chinese medicinal herb of blood stasis dispelling clearing away phlegm, the hard eliminating stagnation that disappears, by the theory of Chinese medical science prescription, it is played a role.
Medicine of the present invention is processed by following component:
The Radix Ginseng 12 gram Radixs Astragali 16 gram Flos Carthamis 12 gram Radix Curcumaes 18 gram Pericarpium Citri Reticulataes 15 gram Radix Aucklandiae 10 gram Rhizoma Belamcandae 15 gram Pollen Typhaes 15 gram Herba Hedyotidis Diffusaes 18 gram Endothelium Corneum Gigeriae Galli 20 gram Herba Salviae Chinensiss 20 grams
Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, every packed medicated powder 8 grams.One after each meal, is used mixing in water for oral taking at twice at two bags of every days.
Medicine of the present invention is a Chinese medicine preparation, and is theoretical according to traditional Chinese medical science prescription, selects that medicine is reasonable, QI invigorating is eliminating evil, the blood stasis dispelling clearing away phlegm, hard eliminating stagnation disappears.Medicine of the present invention, warp is the clinical observation patient for many years, and is evident in efficacy, and lung cancer patient is all had remarkable result.
Clinical drug of the present invention is taken the result and is shown, following advantage is arranged:
It is raw material that the present invention selects natural plant for use, and each component meets the pharmaceutical control law regulation, utilizes the comprehensive function treatment multiple takayasu arteritis of the medicine of respectively distinguishing the flavor of, and no chemicals is harmless to human non-toxic, has no side effect, and is safe and reliable; The present invention is a powder, and effective ingredient scatters and disappears few, and curative effect is high, and is cheap, taking convenience, no any discomfort disease; Medicine of the present invention is obvious to the patients with lung cancer curative effect that refusal operates, and is being superior to chemotherapeutics aspect the prolongation patient life.
For showing the therapeutic effect of medicine of the present invention to pulmonary carcinoma; The present invention does the clinical observation of system through the patient of 300 example refusal operations; And select medical history, the state of an illness, age and refusal operation patients with lung cancer 300 examples suitable to organize as a comparison with traditional therapy (NP chemotherapy regimen); Age 26-84 year, course of disease 1-9; Test group: take medicine of the present invention; Matched group: use the NP chemotherapy regimen.Observation period is 1 year, check after a year, and the pulmonary carcinoma lump is reduced into produce effects, and the pulmonary carcinoma lump does not have increase for effective, and it is invalid that the pulmonary carcinoma lump continues to increase.Clinical comparison result sees table 1.
Table 1: take medicine of the present invention and use observation of curative effect to pulmonary carcinoma NP chemotherapy regimen.
Two groups of effective percentage of table 1 relatively
Annotate: curative effect relatively adopts statistical method, and enumeration data adopts X
2Check, two groups of effective percentage can find out from table 1 P＜0.01 that relatively two groups of effective percentage compare: the experimental group total effective rate is 90%, and matched group is 16.6%, and experimental group obviously is superior to matched group (P＜0.01)
The specific embodiment:
The Radix Ginseng 12 gram Radixs Astragali 16 gram Flos Carthamis 12 gram Radix Curcumaes 18 gram Pericarpium Citri Reticulataes 15 gram Radix Aucklandiae 10 gram Rhizoma Belamcandae 15 gram Pollen Typhaes 15 gram Herba Hedyotidis Diffusaes 18 gram Endothelium Corneum Gigeriae Galli 20 gram Herba Salviae Chinensiss 20 grams; Above-mentioned each component mix homogeneously is ground into 150 order fine powders; Be distributed into bag, every packed medicated powder 8 grams.One after each meal, is used mixing in water for oral taking at twice at two bags of every days.
Claims (1)
- One kind to be used for lung cancer drugs be the powder of being processed by the following weight proportion raw material: the Radix Ginseng 12 gram Radixs Astragali 16 gram Flos Carthamis 12 gram Radix Curcumaes 18 gram Pericarpium Citri Reticulataes 15 gram Radix Aucklandiae 10 gram Rhizoma Belamcandae 15 gram Pollen Typhaes 15 gram Herba Hedyotidis Diffusaes 18 gram Endothelium Corneum Gigeriae Galli 20 gram Herba Salviae Chinensiss 20 grams; Above-mentioned each component mix homogeneously is ground into 150 order fine powders; Be distributed into bag, every packed medicated powder 8 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103852955A CN102430095A (en) | 2011-11-15 | 2011-11-15 | Medicine for treating lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103852955A CN102430095A (en) | 2011-11-15 | 2011-11-15 | Medicine for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102430095A true CN102430095A (en) | 2012-05-02 |
Family
ID=45978680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103852955A Pending CN102430095A (en) | 2011-11-15 | 2011-11-15 | Medicine for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102430095A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437977A (en) * | 2003-01-13 | 2003-08-27 | 许新琳 | Medicine for treating lung cancer |
-
2011
- 2011-11-15 CN CN2011103852955A patent/CN102430095A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437977A (en) * | 2003-01-13 | 2003-08-27 | 许新琳 | Medicine for treating lung cancer |
Non-Patent Citations (1)
| Title |
|---|
| 郭孝忠等: "肺癌用药规律初探", 《辽宁中医杂志》, vol. 29, no. 05, 25 May 2002 (2002-05-25) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN103830696A (en) | Traditional Chinese medicine for treating pulmonary emphysema | |
| CN103845592A (en) | Traditional Chinese medicine for treating cervical lymph node tuberculosis | |
| CN103007237B (en) | Medicine for treating idiopathic thrombocytopenic purpura (ITP) | |
| CN102526613B (en) | Medicament for treating allergic cutaneous vasculitis | |
| CN105125838A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparing method thereof | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN102430095A (en) | Medicine for treating lung cancer | |
| CN102526622B (en) | Medicine for treating knee-joint bursitis | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN102512546B (en) | Traditional Chinese medicine used for esophageal cancer patients refusing surgery | |
| CN102512589B (en) | Medicine for treating early sudden deafness | |
| CN102512637B (en) | Medicine for treating special chronic sinusitis of patients | |
| CN103655875B (en) | Treatment blood sampling causes the medicine of Patients with Aplastic Anemia venous thrombosis | |
| CN102552569B (en) | Medicine for treating renal artery type arteritis | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof | |
| CN102973803A (en) | Drug for treating hematopathy primary thrombocytopenic purpura | |
| CN103301261A (en) | Medicine for treating transplant kidney main renal venous stenosis | |
| CN102872419A (en) | Medicine used for patients rejecting gastrectomy | |
| CN105079580A (en) | Traditional Chinese medicine composition for treating wind-warm lung-heat disease | |
| CN102406875A (en) | Drug for treating endometriosis interna | |
| CN102526610A (en) | Traditional Chinese medicine for curing multiple takayasu arteritis | |
| CN104606553B (en) | A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20120502 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |